Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
- PMID: 34902334
- DOI: 10.1016/S1470-2045(21)00603-3
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
Abstract
Background: Hepatocellular carcinoma is a frequent consequence of alcohol-related liver disease, with variable incidence among heavy drinkers. We did a genome-wide association study (GWAS) to identify common genetic variants for alcohol-related hepatocellular carcinoma.
Methods: We conducted a two-stage case-control GWAS in a discovery cohort of 2107 unrelated European patients with alcohol-related liver disease aged 20-92 years recruited between Oct 22, 1993, and March 12, 2017. Cases were patients with alcohol-related hepatocellular carcinoma diagnosed by imaging or histology. Controls were patients with alcohol-related liver disease without hepatocellular carcinoma. We used an additive logistic regression model adjusted for the first ten principal components to assess genetic variants associated with alcohol-related hepatocellular carcinoma. We did another analysis with adjustment for age, sex, and liver fibrosis. New candidate associations (p<1 × 10-6) and variants previously associated with alcohol-related hepatocellular carcinoma were evaluated in a validation cohort of 1933 patients with alcohol-related liver disease aged 29-92 years recruited between July 21, 1995, and May 2, 2019. We did a meta-analysis of the two case-control cohorts.
Findings: The discovery cohort included 775 cases and 1332 controls. Of 7 962 325 variants assessed, we identified WNT3A-WNT9A (rs708113; p=1·11 × 10-8) and found support for previously reported regions associated with alcohol-related hepatocellular carcinoma risk at TM6SF2 (rs58542926; p=6·02 × 10-10), PNPLA3 (rs738409; p=9·29 × 10-7), and HSD17B13 (rs72613567; p=2·49 × 10-4). The validation cohort included 874 cases and 1059 controls and three variants were replicated: WNT3A-WNT9A (rs708113; p=1·17 × 10-3), TM6SF2 (rs58542926; p=4·06 × 10-5), and PNPLA3 (rs738409; p=1·17 × 10-4). All three variants reached GWAS significance in the meta-analysis: WNT3A-WNT9A (odds ratio 0·73, 95% CI 0·66-0·81; p=3·93 × 10-10), TM6SF2 (1·77, 1·52-2·07; p=3·84×10-13), PNPLA3 (1·34, 1·22-1·47; p=7·30 × 10-10). Adjustment for clinical covariates yielded similar results. We observed an additive effect of at-risk alleles on alcohol-related hepatocellular carcinoma. WNT3A-WNT9A rs708113 was not associated with liver fibrosis.
Interpretation: WNT3A-WNT9A is a susceptibility locus for alcohol-related hepatocellular carcinoma, suggesting an early role of the Wnt-β-catenin pathway in alcohol-related hepatocellular carcinoma carcinogenesis.
Funding: Ligue Nationale contre le Cancer, Bpifrance, INSERM, AFEF, CARPEM, Labex OncoImmunology, and Agence Nationale de la Recherche.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests ET received research support from Gilead. NG-C received honoraria from Roche, Gilead, and Ipsen, and support for travel and attending meetings from Gilead. CM received research support from Gilead; consulting fees from Gilead, AbbVie, Novartis, Surrozen, and Julius Clinical; support for travel and attending meetings from Gilead and AbbVie; honoraria from Bayer and Astellas; and acted as a scientific advisor to Gilead and Novartis. J-CN received research support from Bayer and Ipsen. J-PB received consulting fees from Bayer, Roche, and Ipsen; honoraria from Bayer, Ipsen, and Roche; support for travel and attending meetings from Bayer, Ipsen, and Roche; and acted as a scientific advisor to Roche. TG received research support from Gilead, honoraria from AbbVie, and acted as a scientific advisor to GoLiver Therapeutics and Promethera Biosciences. PN received research support from Bristol Myers Squibb, Eisai, and Roche; consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Gilead, Eisai, Roche, Ipsen, and Exact Science; honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Gilead, Eisai, Roche, Ipsen, and Exact Science; support for travel and attending meetings from Ipsen and Roche; and acted as a scientific advisor to AstraZeneca, Bayer, Bristol Myers Squibb, Gilead, Eisai, Roche, Ipsen, and Exact Science. All other authors declare no competing interests.
Comment in
-
Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk.Lancet Oncol. 2022 Jan;23(1):14-16. doi: 10.1016/S1470-2045(21)00663-X. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902337 No abstract available.
-
GWAS reveals variants for alcohol-related hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):79. doi: 10.1038/s41575-022-00575-0. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35017673 No abstract available.
Similar articles
-
Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.Am J Gastroenterol. 2018 Oct;113(10):1475-1483. doi: 10.1038/s41395-018-0041-8. Epub 2018 Mar 13. Am J Gastroenterol. 2018. PMID: 29535416
-
PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer. 2019 Feb 1;144(3):533-544. doi: 10.1002/ijc.31910. Epub 2018 Nov 9. Int J Cancer. 2019. PMID: 30289982
-
Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.Gene. 2022 Apr 30;820:146235. doi: 10.1016/j.gene.2022.146235. Epub 2022 Feb 7. Gene. 2022. PMID: 35143946
-
Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies.Gene. 2019 Feb 15;685:143-148. doi: 10.1016/j.gene.2018.11.012. Epub 2018 Nov 4. Gene. 2019. PMID: 30403964 Review.
-
PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease.Am J Gastroenterol. 2015 Jun;110(6):846-56. doi: 10.1038/ajg.2015.137. Epub 2015 May 12. Am J Gastroenterol. 2015. PMID: 25964223 Review.
Cited by
-
Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.Gut. 2023 Feb;72(2):381-391. doi: 10.1136/gutjnl-2022-327196. Epub 2022 Jul 4. Gut. 2023. PMID: 35788059 Free PMC article.
-
Interplay Between Fatty Acids, Stearoyl-Co-A Desaturase, Mechanistic Target of Rapamycin, and Yes-Associated Protein/Transcriptional Coactivator With PDZ-Binding Motif in Promoting Hepatocellular Carcinoma.Gastro Hep Adv. 2022 Aug 3;2(2):232-241. doi: 10.1016/j.gastha.2022.07.017. eCollection 2023. Gastro Hep Adv. 2022. PMID: 39132609 Free PMC article. Review.
-
Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma.Hepatol Forum. 2024 Jul 2;5(3):150-160. doi: 10.14744/hf.2023.2023.0028. eCollection 2024. Hepatol Forum. 2024. PMID: 39006147 Free PMC article. Review.
-
Alcohol-associated liver disease.J Clin Invest. 2024 Feb 1;134(3):e176345. doi: 10.1172/JCI176345. J Clin Invest. 2024. PMID: 38299591 Free PMC article. Review.
-
Risk stratification and early detection biomarkers for precision HCC screening.Hepatology. 2023 Jul 1;78(1):319-362. doi: 10.1002/hep.32779. Epub 2022 Oct 11. Hepatology. 2023. PMID: 36082510 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical